Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Background. Sodium-glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitors are glucose-lowering drugs whose anti-inflammatory properties have recently become useful in tackling metabolic syndromes in chronic inflammatory diseases, including diabetes and obesity. We investigated whether empagliflozin (SGLT2 inhibitor) and gemigliptin (DPP-4 inhibitor) improve inflammatory responses in macrophages, identified signalling pathways responsible for these effects, and studied whether the effects can be augmented with dual empagliflozin and gemigliptin therapy. Methods. RAW 264.7 macrophages were first stimulated with lipopolysaccharide (LPS), then cotreated with empagliflozin, gemigliptin, or empagliflozin plus gemigliptin. We conducted quantitative RT-PCR (qRT-PCR) to determine the most effective anti-inflammatory doses without cytotoxicity. We performed ELISA and qRT-PCR for inflammatory cytokines and chemokines and flow cytometry for CD80, the M1 macrophage surface marker, to evaluate the anti-inflammatory effects of empagliflozin and gemigliptin. NF-κB, MAPK, and JAK2/STAT signalling pathways were examined via Western blotting to elucidate the molecular mechanisms of anti-inflammation. Results. LPS-stimulated CD80+ M1 macrophages were suppressed by coincubation with empagliflozin, gemigliptin, and empagliflozin plus gemigliptin, respectively. Empagliflozin and gemigliptin (individually and combined) inhibited prostaglandin E2 (PGE2) release and COX-2, iNOS gene expression in LPS-stimulated RAW 264.7 macrophages. These three treatments also attenuated the secretion and mRNA expression of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, and IFN-γ, and proinflammatory chemokines, such as CCL3, CCL4, CCL5, and CXCL10. All of them blocked NF-κB, JNK, and STAT1/3 phosphorylation through IKKα/β, MKK4/7, and JAK2 signalling. Conclusions. Our study demonstrated the anti-inflammatory effects of empagliflozin and gemigliptin via IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 pathway downregulation in macrophages. In all cases, combined empagliflozin and gemigliptin treatment showed greater anti-inflammatory properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Empagliflozin was proven to mitigate inflammation by downregulation of the JAK2/STAT1 pathway in macrophages [89].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
NF-κB signaling in inflammation
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.23 · Cited by 8,791
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679 · cited 1×
“NF-κB is a crucial transcription factor for proinflammatory mediators in macrophages [46].”
BackgroundInflammatory links between obesity and metabolic disease
Lumeng, C. N., & Saltiel, A. R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57132 · Cited by 2,319 · cited 1×
“Certain aspects of chronic low-grade inflammation in obesity and metabolic syndrome-related diseases, such as hypertension, atherosclerosis, and diabetes mellitus, have been studied [1].”
BackgroundInflammation as a link between obesity, metabolic syndrome and type 2 diabetes
Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J., & Paquot, N. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.006 · Cited by 1,981
Pathophysiology of acute wound healing
Li, J., Chen, J., & Kirsner, R. (2007) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2006.09.007 · Cited by 1,486
Kaminska, B. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.08.017 · Cited by 1,285 · cited 1×
“MAPKs mediate biological processes and cellular responses to external stimuli, such as LPS [42, 47].”
BackgroundTNF and ROS crosstalk in inflammation
Blaser, H., Dostert, C., Mak, T. W., & Brenner, D. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.12.002 · Cited by 1,008
Kanai, Y., Lee, W. S., You, G., Brown, D., & Hediger, M. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116972 · Cited by 630
Cited by
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
“Empagliflozin was proven to mitigate inflammation by downregulation of the JAK2/STAT1 pathway in macrophages [89].”
BackgroundSodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
Fonseca-Correa, J. I., & Correa-Rotter, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.777861 · Cited by 277
Cai, C., Guo, Z., Chang, X., Li, Z., Wu, F., He, J., Cao, T., Wang, K., Shi, N., Zhou, H., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102288 · Cited by 261
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 191
“SGLT2i - Promote autophagic potential of renal cells (induction of AMPK phosphorylation AMPK) [24] - Decrease activity of mammalian target of rapamycin (mTOR) [24,68] - Decrease synthesis of proinflammatory cytokines: interleukin 1β (IL1β), interleukin 6 (IL6) and tumor necrosis factor α (TNFα) through inhibition of N…”
BackgroundInfluentialScisciola, L., Cataldo, V., Taktaz, F., Fontanella, R. A., Pesapane, A., Ghosh, P., Franzese, M., Puocci, A., Angelis, A. D., Sportiello, L., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1008922 · Cited by 141
“7 macrophages, empagliflozin in association with gemigliptin and Dipeptidyl peptidase4 (DPP-IV) inhibitor reduced gene expression and proinflammatory cytokine and chemokine release through the IKK/NF-κB/JAK2 - STAT1/3, and MKK4/7- JNK pathways (53).”
BackgroundAnti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages
RYKOVA, E. Y., Klimontov, V. V., Shmakova, E. O., Korbut, A. I., Merkulova, T. I., & Kzhyshkowska, J. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041670 · Cited by 100
“This decrease in the proinflammatory response was shown for canagliflozin [111], empagliflozin [100,103,112], and dapagliflozin [103].”
InfluentialMatsumori, A. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.10 · Cited by 95
Chen, X., Hocher, C., Shen, L., Krämer, B. K., & Hocher, B. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00177.2023 · Cited by 84
Panico, C., Felicetta, A., Kunderfranco, P., Cremonesi, M., Salvarani, N., Carullo, P., Colombo, F., Idini, A., Passaretti, M., Doro, R., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062984 · Cited by 80
“61 It has also been shown that SGLT2is increase serum ketone levels.”
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
Heimke, M., Lenz, F., Rickert, U., Lucius, R., & Cossais, F. (2022) · Cells · doi:10.3390/cells11193107 · Cited by 78
Youssef, M. E., El-Fattah, E. E. A., Abdelhamid, A. M., Eissa, H., El-Ahwany, E. G., Amin, N. A., Hetta, H. F., Mahmoud, M. H., Batiha, G. E., Gobba, N. A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.719984 · Cited by 64
“Additionally, it showed an anti-inflammatory effect via the inhibition of NF-κB/JNK/STAT signaling pathways (Lee et al., 2021).”
BackgroundFeijóo‐Bandín, S., Aragón‐Herrera, A., Otero-Santiago, M., Anido‐Varela, L., Moraña‐Fernández, S., Tarazón, E., Roselló‐Lletí, E., Portolés, M., Gualillo, O., González‐Juanatey, J. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105634 · Cited by 63
Lee, S. A., & Riella, L. V. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.02.1435 · Cited by 71
“41 Another in vitro study involving human ventricular cardiac myoblasts revealed that empagli fl ozin mitigated the high glucose-induced DNA demethylation changes in NF-k B and superoxide dismutase 2 genes, and this fi nding was correlated with the decreased reactive oxygen species level and lower…”
BackgroundGohari, S., Reshadmanesh, T., Khodabandehloo, H., Karbalaee‐Hasani, A., Ahangar, H., Arsang‐Jang, S., Ismail‐Beigi, F., Dadashi, M., Ghanbari, S., Taheri, H., et al. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00951-5 · Cited by 65
Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
Zhang, R., Xie, Q., Lu, X., Fan, R., & Tong, N. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01325-9 · Cited by 65
The anti-inflammatory and immunological properties of SGLT-2 inhibitors
Bendotti, G., Montefusco, L. B., Pastore, I., Lazzaroni, E., Lunati, M. E., & Fiorina, P. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02162-9 · Cited by 53
“…promoted an anti-inflammatory effect by inhibiting the expression of CD80 in LPS-induced RAW 264.7 macrophages, as well as by reducing the release of proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, and IFN-γ, and proinflammatory chemokines, such as CCL3, CCL4, CCL5, and CXCL10 [77].”
BackgroundInfluentialImmunomodulation and immunopharmacology in heart failure
Markousis‐Mavrogenis, G., Baumhove, L., Al‐Mubarak, A. A., Aboumsallem, J. P., Bömer, N., Voors, A. A., & van der Meer, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00919-6 · Cited by 52
“In LPS-stimulated M1 macrophages, empagli-flozin attenuated the expression of inflammatory mediators (iNOS, TNF, IL-1β, IL-6 and IFNγ) and chemokines (CCL3, CCL4, CCL5 and CXCL10) by reducing NF-κB, JNK, STAT1 and STAT3 phosphorylation 206 .”
Kongmalai, T., Srinonprasert, V., Anothaisintawee, T., Kongmalai, P., McKay, G. J., Attia, J. R., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1182037 · Cited by 45
Wang, Y., Zhu, T., Shi, Q., Zhu, G., Zhu, S., & Hou, F. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008026 · Cited by 43
Balogh, D. B., Wagner, L. J., & Fekete, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097789 · Cited by 38
“Empagliflozin reduced the expression of proinflammatory cytokine and chemokine release through the IKK/NF-κB/JAK2-STAT1/3, and MKK4/7-JNK pathways [38].”
BackgroundRastogi, A., & Januzzi, J. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082824 · Cited by 42
Arvanitakis, K., Koufakis, T., Kotsa, K., & Germanidis, G. S. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106261 · Cited by 39
Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer
Zhou, Q., Xu, J., Xu, Y., Sun, S., & Chen, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176647 · Cited by 38
“In addition, M1 macrophages can induce and enhance the immune response of T cells, thus enhancing the cytotoxic effect on tumors (38).”
BackgroundHeo, Y. J., Lee, N., Choi, S., Jeon, J. Y., Han, S. J., Kim, D. J., KANG, Y. Y., Lee, K. W., & Kim, H. J. (2023) · Mediators of Inflammation · doi:10.1155/2023/2364121 · Cited by 47
“COX-2 and iNOS mRNA and protein expression also markedly increased after lipopolysaccharide stimulation [42].”
BackgroundSelf-citationPeptide-Based Vaccines and Therapeutics for COVID-19
Bagwe, P. V., Bagwe, P., Ponugoti, S. S., & Joshi, S. V. (2022) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-022-10397-y · Cited by 36
“It decreases the CRP levels that are increased in the infected condition and is reported to reduce complications of diabetes mellitus associated with COVID-19 (Katsiki and Ferrannini 2020; Lee et al. 2021; Sazgarnejad et al. 2021).”
BackgroundOn the wake of metformin: Do anti-diabetic SGLT2 inhibitors exert anti-aging effects?
Scisciola, L., Olivieri, F., Ambrosino, C., Barbieri, M., Rizzo, M. R., & Paolisso, G. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102131 · Cited by 37
“…its anti-inflammatory capabilities, reducing the production of IL-6, TNF-α , monocyte chemoattractant protein-1 (MCP-1), interferon-gamma (IFN-γ ), P-selectin, and intracellular adhesion molecules (ICAM-1) in the hearts of diabetic Zucker rats (Elrakaybi et al., 2022; Lee et al., 2021).”
BackgroundPolychronopoulou, E., Bourdon, F., & Teta, D. (2024) · Frontiers in Nephrology · doi:10.3389/fneph.2024.1332397 · Cited by 33
Sun, H.-Y., Wu, J. H., Wang, R., Zhang, S., Xu, H., Kaznacheyeva, E. V., Lu, X., Ren, H., & Wang, G. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01030-1 · Cited by 33
Arvanitakis, K., Koufakis, T., Kalopitas, G., Papadakos, S. P., Kotsa, K., & Germanidis, G. S. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102935 · Cited by 35
Subudhi, L., Thatoi, H., & Banerjee, A. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156364 · Cited by 32
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Złotek, M., Kurowska, A., Herbet, M., & Piątkowska‐Chmiel, I. (2023) · Biomedicines · doi:10.3390/biomedicines11113035 · Cited by 32
“This suggests that canagliflozin therapy may help reverse inflammatory processes at the molecular level [239].”
BackgroundUDP-glucose sensing P2Y14R: A novel target for inflammation
Zhang, J.-Z., Shi, N.-R., Wu, J., Wang, X., Illés, P., & Tang, Y. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109655 · Cited by 32
Vaziri, Z., Saleki, K., Aram, C., Alijanizadeh, P., Pourahmad, R., Azadmehr, A., & Ziaei, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115686 · Cited by 31
Xie, L., Xiao, Y., Tai, S., Yang, H., Zhou, S., & Zhou, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.836849 · Cited by 35
Moneva-Sakelarieva, M. G., Kobakova, Y. A., Konstantinov, S., Momekov, G., Ivanova, S., Atanasova, V. P., Chaneva, M. S., Tododrov, R., Bashev, N. Z., & Atanasov, P. Y. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e146759 · Cited by 38
“Gemigliptin has been shown to have anti-inflammatory effects by regulating the IKK/NF-kB, MKK7/JNK, and JAK2/STAT1 pathways in macrophages (Lee et al. 2021).”
Taylor, E. B., Hall, J. E., & Mouton, A. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107761 · Cited by 29
Salama, R. M., Ahmed, R. H., Farid, A. A., AbdElSattar, B. A., AbdelBaset, R. M., Youssef, M. E., & Wakeel, S. A. E. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109686 · Cited by 22
Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure
Gotzmann, M., Henk, P., Stervbo, U., Blazquez‐Navarro, A., Mügge, A., Babel, N., & Westhoff, T. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134458 · Cited by 22
Makaro, A., Świerczyński, M., Pokora, K., Sarniak, B., Kordek, R., Fichna, J., & Sałaga, M. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01227-8 · Cited by 26
“7 cells (Lee et al. 2021; Liu et al. 2021; Xu et al. 2018).”
BackgroundPiperis, C., Marathonitis, A., Anastasiou, A., Theofilis, P., Mourouzis, K., Giannakodimos, A., Tryfou, E. S., Oikonomou, E. K., Siasos, G., & Tousoulis, D. (2024) · Biomedicines · doi:10.3390/biomedicines12102314 · Cited by 28
Wang, X., Bakar, M. H. A., Liqun, S., Kassim, M. A., Shariff, K. A., & Karunakaran, T. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119560 · Cited by 24
Heo, Y.-J., Lee, N., Choi, S., Jeon, J., Han, S. J., Kim, D. J., KANG, Y. Y., Lee, K. W., & Kim, H. J. (2022) · Biomedicines · doi:10.3390/biomedicines10051032 · Cited by 23
Self-citationOuyang, G., Wang, N., Tong, J., Sun, W., Yang, J., & Wu, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28400 · Cited by 29
Farrokh-Eslamlou, N., Momtaz, S., Niknejad, A., Hosseini, Y., Mahdaviani, P., Ghasemnejad‐Berenji, M., & Abdolghaffari, A. H. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03088-6 · Cited by 21
“Moreover, it inhibited nuclear factor kappa betta (NF-κB), c-Jun N-terminal kinases (JNK), Janus kinase/signal transducers, and transcription (JAK/STAT) pathways activation (Lee et al. 2021).”
Zheng, C., Xuan, W., Chen, Z., Zhang, R., Huang, X., Zhu, Y., Ma, S., Chen, K., Chen, L., He, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.848310 · Cited by 22
Camilli, M., Viscovo, M., Maggio, L., Bonanni, A., Torre, I., Pellegrino, C., Lamendola, P., Tinti, L., Teofili, L., Hohaus, S., et al. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01059-9 · Cited by 22
He, Z., Zhou, Y., Liu, J., Li, N., & Fan, H. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1601501 · Cited by 26
Wang, A., Li, Z., Zhuo, S., Gao, F., Zhang, H., Zhang, Z., Ren, G., & Ma, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.857952 · Cited by 22
“The involvement that JNK plays in cardiac hypertrophy and I/R is less clear because JNK activation is most likely a dynamic signal transduction event that can be modified by the nature of the stimuli and that different JNK (JNK1-3) isoforms may play Frontiers in Cardiovascular Medicine | www.frontiersin.org 12 May 202…”
BackgroundInfluentialElbaz, E. M., Darwish, A., Gad, A. M., Rahman, A. A. S. A., & Safwat, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175993 · Cited by 21
Arefin, A., & Gage, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054785 · Cited by 17
Huang, Y., Zhao, C., Zheng, G., Yuan, Y., Gong, L., Liu, R., & An, J. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00436 · Cited by 16
Elsayed, M. O. K., Moustafa, Y. M., Mehanna, E. T., Elrayess, R. A., El-Sayed, N. M., & Hazem, R. M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122354 · Cited by 15
Gholami, M., Coleman‐Fuller, N., Salehirad, M., Darbeheshti, S., & Motaghinejad, M. (2024) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_5_23 · Cited by 16
Evaluation of empagliflozin efficacy as a promising anti-aging treatment in mice: In-vivo study
Obaid, K. A., & Fawzi, H. A. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e116184 · Cited by 17
“This effect is achieved by inhibiting COX-2, iNOS, cytokine, and chemokine mRNA expression in RAW 264.7 macrophages (Lee et al. 2021).”
BackgroundInfluentialClinical pharmacology of SGLT-2 inhibitors in heart failure
Velliou, M., Polyzogopoulou, E., Ventoulis, I., & Parissis, J. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2173574 · Cited by 20
Lv, C., Hu, C., Zhu, C., Wan, X., Chen, C., Ji, X., Qin, Y., Lü, L., & Guo, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115963 · Cited by 19
Riemma, M. A., Mele, E., Donniacuo, M., Telesca, M., Bellocchio, G., Castaldo, G., Rossi, F., Angelis, A. D., Cappetta, D., Urbanek, K., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1422740 · Cited by 14
Redefining SGLT2 inhibitors through cytoprotective mechanisms
Stanković, S., Miloradović, Z., Petrovič, V., & Stoiljković, M. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178647 · Cited by 13
Li, S., Wang, J., Chen, Y., Cheng, Y., Wang, Y., Xu, N., Wang, H., Wang, L., Chi, Y.-F., Ye, X., et al. (2025) · Inflammation · doi:10.1007/s10753-025-02258-9 · Cited by 16
“## P < 0.01 versus Ctrl; * P < 0.05, ** P < 0.01 versus DKD by one-way ANOVA with Tukey’s post doc analysis and IL-23[51], decrease the levels of IL-6 and IL-1β in an LPS-induced lung injury model[52], and inhibit the activation of NLRP3/ASC inflammasome in cardiac fibroblasts of DKD[53].”
InfluentialAli, M. A., Michel, H. E., Menze, E. T., Tadros, M., & Wahdan, S. A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177525 · Cited by 12
Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
Jing, Y., Yang, R., Chen, W., & Ye, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.898718 · Cited by 12
Wang, S., Li, H., Chen, T., Zhou, H., Zhang, W., Lin, N., Yu, X., Lou, Y., Li, B., Yinwang, E., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03375-w · Cited by 13
Peikert, A., Vacca, A., Norata, G. D., Schiattarella, G. G., & Osto, E. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.012674 · Cited by 22
Abdel-Lah, E. S., Sherkawy, H. S., Mohamed, W. H., Fawy, M. A., Hasan, A. A., Muhammed, A. A., Taha, A. F., Tony, A. A., Hamad, N., & Gamea, M. G. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01755-5 · Cited by 13
“In addition, it inhibited NF-κB/JNK/STAT signaling pathways, resulting in anti-inflammatory effects (Lee et al. 2021).”
Pleiotropic effects of SGLT2 inhibitors: A focus on macrophage-mediated action
Shu, B., Chen, X., Liu, Z., Tang, H., Yang, B., & Fu, C. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108046 · Cited by 21
Empagliflozin Protects against Haloperidol Experimentally-Induced Ovarian Toxicity
Abdelzaher, W. Y., WAARD, M. M. D., Abdelmonaem, A. A., Ali, D., El‐Tahawy, N. F. G., Rifaai, R. A., Mohamed, H. A., Shaheen, K., El-Din, M. A. Z., Welson, N. N., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020168 · Cited by 10
The impact of SGLT2 inhibitors on αKlotho in renal MDCK and HK-2 cells
Wolf, L., Föller, M., & Feger, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1069715 · Cited by 13
“As a matter of fact, such effects exist and play a role in nephro- and cardioprotection by SGLT2 inhibitors: Among them are antiinflammatory properties (51, 52).”
BackgroundIwamoto, Y., Kimura, T., Dan, K., Iwamoto, H., Sanada, J., Fushimi, Y., Katakura, Y., Shimoda, M., Nogami, Y., Shirakiya, Y., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15548 · Cited by 12
Repurposing metabolic drugs as anti-inflammatory agents
Hogan, A. E., Davis, C., Jenkins, B. J., Jones, N., & O'Shea, D. B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.07.003 · Cited by 14
Chu, W., Li, Y., Li, J., Lin, J. H., Li, M., Wang, J., He, J., Zhang, Y., Yao, J., Jin, X., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114902 · Cited by 12
Dolanbay, S. N., Şirin, S., & Aslım, B. (2023) · Fitoterapia · doi:10.1016/j.fitote.2023.105652 · Cited by 9
Koch, B., Fuhrmann, D. C., Schubert, R., Geiger, H., Speer, T., & Baer, P. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031811 · Cited by 11
“Some studies used so-called supra-pharmacological concentrations up to 100 μM [32,38,42,48].”
BackgroundThe Impact of Pharmacotherapy for Heart Failure on Oxidative Stress—Role of New Drugs, Flozins
Bodnar, P., Mazurkiewicz, M., Chwalba, T., Romuk, E. B., Ciszek-Chwalba, A., Jacheć, W., & Wojciechowska, C. (2023) · Biomedicines · doi:10.3390/biomedicines11082236 · Cited by 12
“In this study, the combination of empagliflozin and gemigliptin was found to have more potent antiinflammatory properties [178].”
BackgroundConstantinesco, N. J., Chinnappan, B., DeVito, L., Moras, C., Srikanth, S., García-Hernández, M. D. L. L., Rangel‐Moreno, J., & Gopal, R. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2300077 · Cited by 9
The Role of Macrophages in Cardiac Function and Disease
Prevete, N., & Sorriento, D. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4040026 · Cited by 8
The Mechanism and Treatment of Cognitive Dysfunction in Diabetes: A Review
Hou, Y., Chen, Z., Cheng, J., Li, G., Yin, L., & Gao, J. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2480-7826 · Cited by 10
“…N-terminal kinase (JNK) and signal transducers and activators of transcription 1 and 3 (STAT1/3) phos - phorylation through the IκB kinase/NF-κB, mitogen-activated pro - tein kinase 7/JNK, and Janus kinase 2/STAT1 pathways, exerting an anti-inflammatory effect to improve cognitive function [88].”
Wang, L., Ding, S., Hu, Y., Su, J., Zhu, G., Hong, H., Hou, B., Dong, Z., Xue, Z., Wang, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1513895 · Cited by 13
Wu, X., Li, L., Jinhabure, Xiaofeng, & Eerdunchaolu (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118210 · Cited by 6
Hwang, Y. S., Jang, J., Park, S., Kim, A., Jang, J.-H., Yoon, H. R., Yoon, S. R., Park, J. H., Cho, H. J., & Lee, H. G. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.988309 · Cited by 6
“Since the LPS-induced inflammatory responses are dependent on STAT and NF-κB activity (26), we investigated the relevance of these transcription mediators on the anti-inflammatory effects of PFIE.”
BackgroundOuyang, G., Li, W., Sun, W., San, J., Dai, M., Wei, P., Yang, J., & Wu, G. (2025) · Poultry Science · doi:10.1016/j.psj.2025.106184 · Cited by 6
“Lee N and others found that inhibition of the JAK2-STAT1 signaling pathway inhibited LPS-induced polarization of M1-type macrophages and attenuated the expression levels of related pro-inflammatory cytokines (Lee et al., 2021; Ma et al., 2023; Wan et al., 2025).”
SGLT2 Inhibitors Protect Cardiomyocytes From Myocardial Infarction: A Direct mechanism?
Zhang, J., Zhang, F., & Ge, J. (2022) · Future Cardiology · doi:10.2217/fca-2022-0058 · Cited by 6
Lim, E. H., Mun, S., Kim, J.-J., Chang, D., & Yee, S. (2022) · BioMed Research International · doi:10.1155/2022/2717196 · Cited by 5
“JNKs are activated through the sequential activation of protein kinases containing two dual-speci fi city MAP kinase kinases (MKK4 and MKK7) [21, 22].”
Baufays, C., Cumps, J., Dufeys, C., Ginion, A., Bertrand, L., Horman, S., Beauloye, C., & Marino, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010098 · Cited by 5
“Interestingly, empagliflozin has been shown to inhibit this pathway in macrophages [72,73], raising the possibility of similar effects in fibroblasts, though this remains to be confirmed.”
Merlo, M., Bassetto, G., Cannata, A. N., Aimo, A., Autore, C., Bauce, B., Biagini, E., Cappelli, F., Castelletti, S., D’Ascenzi, F., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15231 · Cited by 7
Alhaddad, A., Mosalam, E. M., AboShabaan, H. S., Sallam, A. S., Mahfouz, M. M., Elhosary, E., Mohammed, A. A., Metwally, E. M., Shaldam, M. A., & Ghoneim, M. E.-S. (2025) · Pharmaceuticals · doi:10.3390/ph18030405 · Cited by 6
Tracking hepcidin level in induced type 2 diabetic rats and how Empagliflozin affects its level
Ali, R. B., Ahmed, M. H., Ibrahim, H. K., & Mahmood, H. S. (2022) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.47750/jptcp.2022.965 · Cited by 5
Tsai, M., Lee, W., Huang, S., Huang, C.-C., Wang, Y., Yuan, C., Wang, C.-C., Liu, C.-H., Huang, N., Chang, Y., et al. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117512 · Cited by 3
Matuszewski, W., Tomaszek, L., Szklarz, M., Górny, J. M., Kordas, B., Rutkowska, J., & Juranek, J. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186348 · Cited by 4
Rodakova, K. S., Gancarčíková, S., Demečková, V., Lauko, S., Rynikova, M., Andrejčáková, Z., Spišáková, D., Fusek, M., Vlčková, R., Strompfová, V., et al. (2026) · Applied Sciences · doi:10.3390/app16115529 · Cited by 3
Chen, P., Long, J., Zhang, J., Xie, F., Wu, W., Tian, Z., Zhang, S., & Yu, K. (2024) · Inflammation Research · doi:10.1007/s00011-023-01833-w · Cited by 4
“5C), which have been shown to attract CD8 + T cells [37], and their expression is increased when the JAK signaling pathway is activated [38].”
BackgroundAnti-inflammatory effect of luteoloside against methylglyoxal induced human dental pulp cells
Kim, J., Man, P. P., Jang, S., & Yi, H. (2024) · Journal of Applied Biomedicine · doi:10.32725/jab.2024.002 · Cited by 3
Nomura, S., Taniura, T., Ichikawa, J., Iwama, A., & Ito, T. (2024) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296241302082 · Cited by 3
Quantitative analysis of Tr1 lymphocytes in patients with type 2 diabetes mellitus
Knott-Torcal, C., de la Blanca, N. S., Serrano-Somavilla, A., Martínez‐Hernández, R., Sampedro-Nuñez, M. A., Ruiz-Roso, M. B., Jiménez-Blanco, S., González‐Amaro, R., González-Baranda, L., Garcimartín, A., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02250-w · Cited by 4
“In addition, it has been reported that GLP-1-RA could exert a regulatory role on lymphocyte proliferation, the maintenance of Treg cells and the activation of transcription factor NF-κB [20–22].”
BackgroundTekin, B. G., & Pektaş, E. (2024) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-024-03638-0 · Cited by 3
Jung, W. K., Park, S., Yu, H. Y., & Kim, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29362 · Cited by 3
“Previous in vitro and in vivo experiments have shown that gemigliptin exhibits several additional activities, including anti-glycation W.K. Jung et al. and anti-inflammatory effects [22,26].”
Novel therapeutic agents for cardiometabolic risk mitigation in heart transplant recipients
Gorrai, A., FARR, M. A., O’Hara, P. J., Beaini, H., HENDREN, N. S., Wrobel, C. A., Hardin, E. A., McGuire, D. K., Khera, A., Wang, T. J., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.12.006 · Cited by 3
Yang, Q., Gao, J., Wang, T., Ding, J.-C., & Hu, P. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s429096 · Cited by 2
“7 macrophages 16 Further animal experiments demonstrated Empagliflozin’s inhibitory effects on the inflammatory response mediated by the IL-17/IL-23 axis, thus reducing liver injury in type 2 diabetic mice with non-alcoholic fatty liver.”
BackgroundOnar, L. Ç., Güner, E., & Yilmaz, I. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15082873 · Cited by 2
“Finally, anti-inflammatory interactions suggested by our docking data may be related to reduced NLRP3 inflammasome activation and NF-κ B signaling, processes implicated in postoperative myocardial and renal injury [39,40].”
SGLT2 Inhibitors in Alzheimer’s Disease: Biochemical Insights and Therapeutic Potential
Mazzeo, P., Vietri, M., Tecce, N., Delizia, A., Remondelli, V., Ciaglia, T., Dio, A. D., Corletti, L., Pizzuti, C. G., Pepe, G., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27115051 · Cited by 2
“Treatment of RAW 264.7 macrophages with increasing concentrations of em-pagliflozin significantly inhibited mRNA expression of inflammatory mediators, indicating a direct inhibitory effect on JAK2/STAT1-dependent transcriptional activity [153,154].”
Influential
Metadata
- Authors
- Lee, N., Heo, Y. J., Choi, S.-E., Jeon, J. Y., Han, S. J., Kim, D. J., Kang, Y., Lee, K. W., & Kim, H. J.
- Affiliations
- Ajou University (KR)
- Corresponding author
- Kim, Hae Jin
- ORCID
- Venue
- Journal of Immunology Research
- Publisher
- Wiley
- Published
- 2021-06-02
- Volume
- 2021
- Pages
- 1-11
- ISSN
- 2314-7156 (ISSN-L)
- 2314-8861
- PMC
- PMC8192181
- OpenAlex
- W3169937201
- Cited by
- 139
- References
- 66
- Citations by year
- 2026: 19 · 2025: 30 · 2024: 29 · 2023: 36 · 2022: 20 · 2021: 5
- FWCI
- 16.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Immunology Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- AJOU Open Repository (Ajou University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation of Korea (NRF-2020R1F1A1074019)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- empagliflozin, gemigliptin, SGLT2 inhibitors, DPP-4 inhibitors, anti-inflammatory activity, macrophages, lipopolysaccharide, NF-κB signaling, JNK signaling, JAK2/STAT3, M1 macrophages, inflammatory cytokines, chemokines, prostaglandin E2, cyclooxygenase-2, inducible nitric oxide synthase, dual therapy, diabetes mellitus, obesity
- MeSH terms
- RAW 264.7 Cells, Sodium-Glucose Transporter 2 Inhibitors, Animals, Anti-Inflammatory Agents, Benzhydryl Compounds, Glucosides, Lipopolysaccharides, Macrophage Activation, Macrophages, Piperidones, Pyrimidines, Signal Transduction, NF-kappa B, MAP Kinase Kinase 4, MAP Kinase Kinase 7, STAT1 Transcription Factor, Mice, I-kappa B Kinase, Janus Kinase 2, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.